VivoSeq
Infectious Disease

Tinea Pedis

28

Pipeline Programs↗

3

Active Trials↗

14

Companies Involved↗

Tinea Pedis is an emerging landscape with 28 programs across 14 companies. The most active players are Sinomune Pharmaceutical Co., Ltd, GSK, WestVac Biopharma Co., Ltd.. 4 therapies are approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

51/100

Pipeline Velocity

6/100

Mech. Concentration

60/100

Completion Rate

90/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Sinomune Pharmaceutical Co., Ltd

3 programs

Phase 1GSK logo

GSK

1 program

Phase 1W

WestVac Biopharma Co., Ltd.

1 program

Phase 1N

Nitric BioTherapeutics, Inc

1 program

Phase 2T

Tinea Pharmaceuticals

1 program

Phase 2T

Therapeutics, Inc.

6 programs

Phase 2

Pipeline

Programs by Phase

Analysis

Trial Status

47

clinical trials

Completed36 · 77%
Unknown status4 · 9%
Terminated3 · 6%
Not yet recruiting2 · 4%
Recruiting1 · 2%
Withdrawn1 · 2%

Clinical Trials

Trial Activity

47 trials

Topical Tolnaftate Stick for Tinea Pedis: An Open-Label Interventional Study
Recruiting·PPropedix, Inc.·Phase 2·NCT07245667·150 enrolled
Efficacy of Tropical Sertaconazole Nitrate 2% Vs Clotrimazole 1% for Tinea Pedis
Not yet recruiting·JJinnah Postgraduate Medical Centre·Phase 4·NCT06869681·100 enrolled
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Different Concentrations of ZYG24004 in Participants With Tinea Pedis Caused by Dermatophytes
Not yet recruiting·SSinomune Pharmaceutical Co., Ltd·Phase 1·NCT07668999·64 enrolled
Clinical Trial Comparing BL123 Versus Ketoconazole in Patients With Tinea Pedis
Completed·—·Phase 2·NCT02824926·60 enrolled
A Trial to Evaluate the Safety and and Tolerability of DBI-001 in Patients With Tinea Pedis
Completed·DDermBiont, Inc.·Phase 2·NCT04152226·12 enrolled
Safety of a Topical Antifungal Treatment for Tinea Cruris, Tinea Pedis and Tinea Corporis
Completed·TTinea Pharmaceuticals·Phase 3·NCT01349998·604 enrolled
Safety and Equivalence of a Generic Ciclopirox Olamine Cream Compared to the Reference Ciclopirox Cream 0.77% for the Treatment of Tinea Pedis
Completed·PPadagis LLC·Phase 3·NCT00802672·561 enrolled
Maximal Use of Luliconazole Cream 1% in Pediatric Participants With Moderate to Severe Tinea Pedis or Tinea Cruris
Completed·BBausch Health Americas, Inc.·Phase 4·NCT02767271·30 enrolled
Topical Antifungal Treatment for Tinea Pedis
Completed·MMedicis Global Service Corporation·Phase 3·NCT01396811·322 enrolled
A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Moderate - Severe Interdigital Tinea Pedis
Completed·VViamet·Phase 2·NCT01891305·50 enrolled
Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Pedis
Completed·MMerz North America, Inc.·Phase 3·NCT00750139·707 enrolled
Safety and Efficacy of Econazole Nitrate Foam 1% in Subjects With Tinea Pedis
Completed·AAmDerma·Phase 3·NCT01353976·264 enrolled
A Study Comparing the Efficacy of TA103 and the Placebo Control in the Treatment of Interdigital Tinea Pedis.
Completed·Sun Pharmaceutical Industries, Inc. logoSun Pharmaceutical Industries, Inc.·Phase 1·NCT04883593·160 enrolled
Multicenter Study of the Efficacy and Safety of Luliconazole Cream in Tinea Pedis (Athlete's Foot)
Completed·TTinea Pharmaceuticals·Phase 2·NCT00869336·147 enrolled
Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis
Completed·MMerz North America, Inc.·Phase 3·NCT01290341·860 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)